This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

In Age Of Patent Expiration, Planning Groups For New Pharma Products Growing In Importance

CHAPEL HILL, N.C., March 9, 2013 /PRNewswire/ -- New product launch groups in the bio-pharmaceutical industry are often faced with dueling pressures of efficiently developing new products with minimum risk and maximum value. In addition, new product commercialization efforts have taken on increased importance in recent years. With the expiration of patents becoming a looming concern across the biopharma industry, individual companies must now, more than ever, find a way to effectively develop new products in a timely manner.

To address various issues related to the critical elements of the new product planning (NPP) function in bio-pharma companies, Best Practices, LLC completed a benchmarking study. The report, " Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability," addresses the critical roles and structure of NPP groups.

The report provides professionals with actionable insights into critical aspects of the NPP function, such as coordinating regional and global efforts and carrying out dozens of activities that generate commercial insights. Other key study topics include:

  • Benchmarks of NPP group structures, roles, responsibilities, and attributes
  • Assessments of the levers of impact and  effectiveness
  • Definitions of interactions and optimal working relationships between Regional and Global NPP groups
  • Discoveries surrounding the full set of activities NPP groups perform, their timing, intended outcomes, and value for the organization
  • Insights into the future of the NPP function

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from over a dozen of the participating companies.

In addition, Best Practices has found that the role of the NPP function has expanded and has continued to change in recent years. In order to expand upon previous research and benchmarks, Best Practices recently launched a new study that focuses on the importance of the NPP function in the biopharmaceutical industry.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs